Page last updated: 2024-08-26

artenimol and navitoclax

artenimol has been researched along with navitoclax in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Budhraja, A; Churchman, ML; Finkelstein, D; Kaminska, E; Kothari, A; Mullighan, CG; Opferman, JT; Panetta, JC; Turnis, ME; Xu, H; Yang, X	1
An, Z; Li, P; Liu, J; Qi, M; Qi, Y; Shao, H; Wu, H; Xiao, H; Yan, X; Yang, W; Zhan, Y	1

Other Studies

2 other study(ies) available for artenimol and navitoclax

Article	Year
Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Dec-15, Volume: 23, Issue:24 Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Artemisinins; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Leukemia, B-Cell; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Xenograft Model Antitumor Assays	2017
Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and Survivin expression to potentiate ABT-263-induced apoptosis in Non-small Cell Lung Cancer cells harboring EGFR or RAS mutation. Biochemical pharmacology, 2018, Volume: 150 Topics: A549 Cells; Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Artemisinins; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Female; Gene Expression Regulation, Enzymologic; Genes, ras; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; STAT3 Transcription Factor; Sulfonamides; Survivin; Xenograft Model Antitumor Assays	2018

Article

Year

Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL

Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Dec-15, Volume: 23, Issue:24

Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Artemisinins; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Leukemia, B-Cell; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Xenograft Model Antitumor Assays

2017

Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and Survivin expression to potentiate ABT-263-induced apoptosis in Non-small Cell Lung Cancer cells harboring EGFR or RAS mutation.

Biochemical pharmacology, 2018, Volume: 150

Topics: A549 Cells; Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Artemisinins; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Female; Gene Expression Regulation, Enzymologic; Genes, ras; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; STAT3 Transcription Factor; Sulfonamides; Survivin; Xenograft Model Antitumor Assays

2018